[1] Schwartz DA, Graham AL. Potential maternal and infant outcomes from (Wuhan) coronavirus 2019-nCoV infecting pregnant women: lessons from SARS, MERS, and other human coronavirus infections. Viruses. 2020;12(2):194. https://doi.org/10.3390/v12020194.
[2] Cascella M, Rajnik M, Cuomo A, Dulebohn SC, Di Napoli R. Features, evaluation and treatment coronavirus (COVID-19). InStatpearls [internet] 2020. StatPearls Publishing.
[3] Borges do Nascimento IJ, Cacic N, Abdulazeem HM, von Groote TC, Jayarajah U, Weerasekara I, Esfahani MA, Civile VT, Marusic A, Jeroncic A, Carvas Junior N. Novel coronavirus infection (COVID-19) in humans: a scoping review and meta-analysis. Journal of clinical medicine. 2020;9(4):941. https://doi.org/10.3390/jcm9040941.
[4] (CSSE) CfSSaE. global statistics of COVID-19 2020.
[5] Li H, Liu Z, Ge J. Scientific research progress of COVID‐19/SARS‐CoV‐2 in the first five months. Journal of cellular and molecular medicine. 2020;24(12): 6558-70. https://doi.org/10.1111/jcmm.15364.
[6] Sohrabi C, Alsafi Z, O’Neill N, Khan M, Kerwan A, Al-Jabir A, Iosifidis C, Agha R. World Health Organization declares global emergency: A review of the 2019 novel coronavirus (COVID-19). International Journal of Surgery. 2020;76:71-76. https://doi.org/10.1016/j.ijsu.2020.02.034.
[7] Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention. Jama. 2020;323(13):1239-42. doi:10.1001/jama.2020.2648.
[8] Ather A, Patel B, Ruparel NB, Diogenes A, Hargreaves KM. Coronavirus disease 19 (COVID-19): implications for clinical dental care. Journal of endodontics. 2020;46(5):584-95. https://doi.org/10.1016/j.joen.2020.03.008.
[9] Kalil AC. Treating COVID-19—off-label drug use, compassionate use, and randomized clinical trials during pandemics. Jama. 2020;323(19):1897-8. doi:10.1001/jama.2020.4742.
[10] Pilkington V, Pepperrell T, Hill A. A review of the safety of favipiravir–a potential treatment in the COVID-19 pandemic?. Journal of Virus Eradication. 2020;6(2):45.
[11] Mitjà O, Clotet B. Use of antiviral drugs to reduce COVID-19 transmission. The Lancet Global Health. 2020;8(5):e639-40. https://doi.org/10.1016/S2214-109X(20)30114-5.
[12] Xuan Y. Initial clinical results announced for favipiravir treatment of novel coronavirus pneumonia-viral clearance in four days. Biodiscover. 2020.
[13] Chen C, Huang J, Cheng Z, Wu J, Chen S, Zhang Y, Chen B, Lu M, Luo Y, Zhang J, Yin P. Favipiravir versus arbidol for COVID-19: a randomized clinical trial. MedRxiv. 2020.
[14] Moher D, Liberati A, Tetzlaff J, Altman DG, Altman D, Antes G, Atkins D, Barbour V, Barrowman N, Berlin JA, Clark J. Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement (Chinese edition). Journal of Chinese Integrative Medicine. 2009;7(9):889-96. 10.3736/jcim20090918.
[15] Higgins JP, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD, Savović J, Schulz KF, Weeks L, Sterne JA. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. Bmj. 2011;343:d5928.
[16] Cai Q, Yang M, Liu D, Chen J, Shu D, Xia J, Liao X, Gu Y, Cai Q, Yang Y, Shen C. Experimental treatment with favipiravir for COVID-19: an open-label control study. Engineering. 2020. https://doi.org/10.1016/j.eng.2020.03.007.
[17] Kikuchi G, Motokawa Y, Yoshida T, Hiraga K. Glycine cleavage system: reaction mechanism, physiological significance, and hyperglycinemia. Proceedings of the Japan Academy, Series B. 2008;84(7):246-63. https://doi.org/10.2183/pjab.84.246.
[18] De Clercq E. New nucleoside analogues for the treatment of hemorrhagic fever virus infections. Chemistry–An Asian Journal. 2019;14(22):3962-8. https://doi.org/10.1002/asia.201900841.
[19] Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, Shi Z, Hu Z, Zhong W, Xiao G. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell research. 2020;30(3):269-71. https://doi.org/10.1038/s41422-020-0282-0.
[20] Wu R, Wang L, Kuo HC, Shannar A, Peter R, Chou PJ, Li S, Hudlikar R, Liu X, Liu Z, Poiani GJ. An update on current therapeutic drugs treating COVID-19. Current Pharmacology Reports. 2020;6:56–70. https://doi.org/10.1007/s40495-020-00216-7.
[21] Arab-Zozani M, Hassanipour S, GHoddoosi-Nejad D. Favipiravir for treating novel coronavirus (COVID-19) patients: protocol for a systematic review and meta-analysis of controlled trials. medRxiv. 2020.